Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

Also called NCT04169269

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Florida Orthopaedic Institute (from the registry)
Registry
  • NCT NCT04169269
Other papers using this trial's data
  • A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma Journal of orthopaedic trauma, 2022-12-01 DOI, PubMed 36399673

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04169269. Randomized; no masking; primary purpose prevention. Start 2020-01-13 (actual); primary completion 2020-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban
Condition
Venous Thromboembolism
Intervention (Drug)
Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters
Intervention (Drug)
Rivaroxaban 10 milligram Oral Tablet
Lead sponsor
Florida Orthopaedic Institute (class: research network)
Collaborator
Orthopaedic Trauma Association (class: other)

Record details

Record id
cardio:ct-nct04169269
Content hash
d7af6e01ecb5062cc23b6bf32ff252c260bcf4432bbc66622d2a6e067c1fdc7c